New opportunities for preventive anti-inflammatory therapy in the management of patients with moderate and severe COVID-19
- 作者: Gorelov A.1, Kalyuzhin O.2, Bagaeva M.3
-
隶属关系:
- Central Research Institute of Epidemiology of Rospotrebnadzor
- Sechenov First Moscow State Medical University (Sechenov University)
- JSC Valenta Pharm Pharmaceutical Company
- 期: 卷 94, 编号 7 (2022)
- 页面: 872-875
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/109740
- DOI: https://doi.org/10.26442/00403660.2022.07.201729
- ID: 109740
如何引用文章
全文:
详细
The specific feature of new coronavirus infection (COVID-19) is high risk of hyperinflammatory response or cytokine storm development, which underly the pathogenesis of several life-threatening conditions and determine the disease outcomes. Pathophysiological features of COVID-19 justify the search of effective drugs capable to control the hyperinflammatory response.
Aim. To evaluate the efficacy and safety of Aterixen® (1-[2-(1-Мethylimidazol-4-yl)-ethyl]perhydroazin-2,6-dion) for achieving clinical improvement in adult patients hospitalized with moderate and severe COVID-19.
Materials and methods. Multicenter, adaptive, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of Aterixen® , tablets, 100 mg, in patients with COVID-19. The study analysis included 116 patients who, by randomization, were divided into 2 groups: 57 patients were included in the Aterixen® drug group and 59 patients were in the placebo group.
Results and conclusion. Obtained results have shown high efficacy and statistically significant superiority of Aterixen® over placebo. Thus, it allows us to consider it as viable medication for COVID-19 pathogenetic therapy.
作者简介
Aleksandr Gorelov
Central Research Institute of Epidemiology of Rospotrebnadzor
Email: madina.bagaeva@valentapharm.com
ORCID iD: 0000-0001-9257-0171
академик РАН, д-р мед. наук, проф., зам. дир. по научной работе
俄罗斯联邦, MoscowOleg Kalyuzhin
Sechenov First Moscow State Medical University (Sechenov University)
Email: madina.bagaeva@valentapharm.com
ORCID iD: 0000-0003-3628-2436
д-р мед. наук, проф. каф. клинической иммунологии и аллергологии
俄罗斯联邦, MoscowMadina Bagaeva
JSC Valenta Pharm Pharmaceutical Company
编辑信件的主要联系方式.
Email: madina.bagaeva@valentapharm.com
ORCID iD: 0000-0002-4577-1832
медицинский советник
俄罗斯联邦, Moscow参考
- Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020;11:1446. doi: 10.3389/fimmu.2020.01446
- Tang L, Yin Z, Hu Y, Mei H. Controlling Cytokine Storm Is Vital in COVID-19. Front Immunol. 2020;11:570993. doi: 10.3389/fimmu.2020.570993
- Павликова Е.П., Агапов М.А., Малахов П.С., и др. Эмфизема средостения – специфическое осложнение COVID-19 (клиническое наблюдение). Общая реаниматология. 2021;17(2):4-15 [Pavlikova EP, Agapov MA, Malakhov PS, et al. Mediastinal Emphysema as a Specific Complication of COVID-19 (Case Report)]. General Reanimatology. 2021;17(2):4-15 (in Russian)]. doi: 10.15360/1813-9779-2021-2-4-15
- Pasrija R, Naime M. The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease. Int Immunopharmacol. 2021;90:107225. doi: 10.1016/j.intimp.2020.107225
- Потапнев М.П. Цитокиновый шторм: причины и последствия. Иммунология. 2021;42(2):175-88. doi: 10.33029/0206-4952-2021-42-2-175-188
- Стукова М.А., Рыдловская А.В., Проскурина О.В., и др. Фармакодинамическая активность нового соединения XC221GI в in vitro и in vivo моделях вирусного воспаления респираторного тракта. Microbiology Independent Research Journal. 2022;9(1):56-70 [Stukova МА, Rydlovskaya AV, Proskurina OV, et al. In vitro and in vivo pharmacodynamic activity of the new compound XC221GI in models of the viral inflammation of the respiratory tract. Microbiology Independent Research Journal (MIR Journal). 2022;9(1):56-70 (in Russian)]. doi: 10.18527/2500-2236-2022-9-1-56-70
- Временные рекомендации по профилактике, диагностике и лечению коронавирусной инфекции, вызванной SARS-CoV-2, версия 9 от 26.10.2020 [Vremennye rekomendatsii po profilaktike, diagnostike i lecheniiu koronavirusnoi infektsii, vyzvannoi SARS-CoV-2, versiia 9 ot 26.10.2020 (in Russian)].
- National Early Warning Score (NEWS) 2. Available at: https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2. Accessed: 20.01.2022.